| GSK's patient access scheme for Votrient sways NICE - InPharm |
|
|
InPharm Votrient (pazopanib) received the Institute's backing as a first line treatment option for people with advanced renal cell carcinoma who have not received ... Kidney cancer treatment fast tracked for NHS WebMD.Boots.com UK's NICE backs GlaxoSmithKline's Votrient for the first-line treatment of |